Medgenics Inc Appointment of Nominated Adviser and Joint Broker (3654P)

TIDMMEDG TIDMMEDU

RNS Number : 3654P

Medgenics Inc

01 October 2013

 
 Press Release   1 October 2013

Appointment of Nominated Adviser and Joint Broker

Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) ("the Company"), developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announces that Oriel Securities Limited has been appointed as the Company's nominated adviser and joint broker with immediate effect.

About Medgenics

Medgenics is developing and commercializing Biopump(TM), a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis, among others. For more information, please visit www.medgenics.com.

For further information, please contact:

 
 Abchurch Communications 
  Joanne Shears / Jamie Hooper 
  / Harriet Rae 
  harriet.rae@abchurch-group.com      +44 207 398 7719 
 Oriel Securities (NOMAD & Joint 
  Broker) 
  Jonathan Senior / Giles Balleny     +44 207 776 1200 
 SVS Securities plc (Joint Broker) 
  Alex Brearley                       +44 207 638 5600

-Ends-

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCNKDDKOBDKOKK

Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024